Change in the number of votes relating to Biotie Therapies Corp.'s shares

| Source: Biotie Therapies
Biotie Therapies Corp.          Stock Exchange Release    21 August 2014 at
10.00 a.m.

Change in the number of votes relating to Biotie Therapies Corp.'s shares

The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"),
Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie
Therapies Holding AG) has conveyed Biotie shares against consideration pursuant
to the option programs as follows:

 August 2014 Total (5/2011-   Options
                8/2014)      outstanding

   917,693     9,575,772     2,698,627

The conveyance of Biotie shares relates to the option plan of Synosia
Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia")
acquired by Biotie in February 2011. According to such Synosia share option
plan, options have been granted to employees, former directors and consultants.
In connection with the completion of the acquisition of Synosia, the option plan
was amended so that instead of shares in Synosia an aggregate maximum of
14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued
these 14,912,155 shares to its current subsidiary Synosia in connection with the
acquisition to be further conveyed to the option holders when they potentially
exercise their option rights in accordance with the terms and conditions of the
option program.

The conveyed shares previously held as Treasury shares have not carried any
voting rights. The conveyance does not affect the number of registered shares.

After the conveyances the changes are as follows:

 The increase of vote  A total amount of   The number of the   The total number
    of the Company      voting rights:    Company's share held  of registered
      August 2014                         by the Biotie Group       shares
                                              August 2014

        917,693           450,433,515          5,598,883         456,032,398

Turku, 21 August 2014

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900

NASDAQ OMX Helsinki Ltd
Main Media